ArticleNature2019
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 1 pooled it
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
286 citing papers in PubMed, 1 synthesis or guideline pooled it, 417 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- Article
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Engineering CAR-T cells to remodel the mucin-rich cancer cell glycocalyx.bioRxiv : the preprint server for biology · 2026Article
- Article
- Article
- Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering.Research square · 2026Article
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues.Stem cell reports · 2026Article
- Advancing targeted protein degradation: pLIRTAC's role in glioma and CAR-T cell therapy.Autophagy · 2026Article
- Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma.Cancer research · 2026Article
- Genetically modulating the RNA-binding protein Regnase-1 reveals its critical role in regulatory T cell homeostasis and function in vivo.Cell death & disease · 2026Article
- Decoding Regnase-1's role in skin inflammation: potential therapeutic implication for dermatological disorders.Journal of advanced research · 2026Review
- Segmentation-free analysis of live-cell imaging data reveals how T cell modifications influence cancer cell aggregation dynamics.Scientific reports · 2026Article
- Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8Research square · 2026Article
226 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 2 institutions in 1 country.
Jun WeiDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Lingyun LongDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Wenting ZhengDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
Yogesh DhunganaDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Seon Ah LimDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Cliff GuyDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Yanyan WangDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Yong-Dong WangDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Chenxi QianDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Beisi XuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Anil KcDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Jordy SaraviaDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Hongling HuangDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
Jiyang YuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
John G DoenchBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Terrence L GeigerDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
Hongbo ChiDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA. hongbo.chi@stjude.org.
St. Jude Children's Research Hospital · USBroad Institute · US
Funding
Regulation of TH17 plasticity and stemness by mTORC1R01AI131703 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$4.1MTranscriptional and metabolic heterogeneity in T cell differentiationR01AI140761 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$3.9MMetabolic checkpoint in dendritic cell subsets and adaptive immunityR37AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.6MBidirectional signaling in T cell differentiationR01AI150241 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.3MNutrient sensing and lysosomal signaling in regulatory T cells and immune toleranceR01AI150514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2019 to 2023
$2.2MMetabolic checkpoint in TH17 cell differentiationR01AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2014 to 2018
$2.2MTsc1/mTOR axis in immune homeostasis and tumorigenesisR01CA176624 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2014 to 2018
$1.9MIntracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell DataR01GM134382 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YU, JIYANG · 2019 to 2023
$1.7MMetabolic reprogramming of Tregs in tumor immunityR01CA221290 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2017 to 2020
$1.6MNCI NIH HHS R01 CA176624NCI NIH HHS R01 CA221290NIAID NIH HHS R01 AI105887NIAID NIH HHS R01 AI131703NIAID NIH HHS R01 AI140761NIAID NIH HHS R01 AI150241NIAID NIH HHS R01 AI150514NIAID NIH HHS R37 AI105887NIGMS NIH HHS R01 GM134382NIH HHS AI105887NIH HHS AI131703NIH HHS AI140761NIH HHS AI150241NIH HHS AI150514NIH HHS CA221290
Abstract
Adoptive cell therapy represents a new paradigm in cancer immunotherapy, but it can be limited by the poor persistence and function of transferred T cells
Indexed as
Molecular Targeted TherapyAnimalsBasic-Leucine Zipper Transcription FactorsCD8-Positive T-LymphocytesCRISPR-Cas SystemsDisease Models, AnimalFemaleGene DeletionHumansImmunotherapy, AdoptiveLeukemiaLymphocytes, Tumor-InfiltratingMelanomaMiceMitochondriaProtein Tyrosine Phosphatase, Non-Receptor Type 2Basic-Leucine Zipper Transcription FactorsBatf protein, mouseProtein Tyrosine Phosphatase, Non-Receptor Type 2Ptpn2 protein, mouseRibonucleasesSocs1 protein, mouseSuppressor of Cytokine Signaling 1 ProteinZc3h12a protein, mouse
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.